<DOC>
	<DOCNO>NCT02249351</DOCNO>
	<brief_summary>Study ass symptomatic efficacy , safety tolerability talsaclidine patient mild moderate dementia Alzheimer type</brief_summary>
	<brief_title>Efficacy Safety Talsaclidine ( Free Base ) Patients With Mild Moderate Dementia Alzheimer Type</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Male female patient , age : 40 year ( low age genetic Dementia Alzheimer Type ( DAT ) document ) . Patients 85 year need clinically stable state ( investigator 's judgement ) Patient 's educational level &gt; 4 year Patient able understand patient information give inform consent Patient give write informed consent accordance Good Clinical Practice local legislation Patient relative caregiver willing capable support clinical trial ; his/her write informed consent optional Body weight : ≥ 50 kg within +/ 30 % normal weight ( Broca index ) Diagnosis DAT National Institute Neurological communicative DisordersAlzheimer 's Disease Related Disorder Association ( NINCDSADRDA ) criteria MMSscore 10 24 inclusive Rosen ischemia score lower equal two Patient able complete trial examination , hear , speak , read write basic way primary sensorial function intact Any dementia vascular genesis ( Rosen ischemia score &gt; 2 ) Magnetic Resonance Imaging ( MRI ) Computer Tomogram ( CT ) finding make diagnosis DAT unlikely ( scan perform within 12 month study entry ) Any stroke history All secondary dementia ( exclusion diagnosis define NINCDSADRDA criterion ) late complication : Craniocerebral trauma Intoxication ( incl . history alcohol drug abuse ) Cerebral infection ( e.g . neurosyphilis ) Thyroid dysfunction Cerebral dysfunction due metabolic disorder Possible reversible dementia secondary deficiency vitamin B12 , folic acid thyroid hormone . Replacement therapy must start three month visit 1 order exclude dementia due deficiency . Brain tumour ( benign tumour find CT felt clinically relevant may include , i.e . : meningioma ) Down 's syndrome , Parkinson 's disease , Huntington 's chorea , Diffuse Lewy Body Disease ( measure McKeith Criteria specify CTM ) Multiple sclerosis Major depression score &lt; =16 Hamilton Depression Rating Scale ( HAMD ) 17 item scale Depressive pseudodementia Mental retardation Hydrocephalus Epilepsy Endogenous psychosis ( schizophrenia ) Untreated poorly compensate hypertension ( Blood Pressure systolic &gt; 180 and/or diastolic &gt; 110 mmHg ) Hypertension treat reserpine , clonidine βblockers Severe heart disease ( NYHA : III IV ) Any cardiac arrhythmia ( atrial ventricular ) include bradycardia rate &lt; 50 bpm , arrhythmia due second third degree block Lown : IIIV , Electrocardiogram &gt; 30 ventricular extrasystoles/hour , multifocal multiform repetitive form ventricular extrasystole , pacemaker allow Bronchial asthma phase exacerbation , inducible aspirin Nonsteroidal antiinflammatory drug , require acute pharmacologic intervention previous year Diabetes , type I II , active treatment either insulin oral agent , diabetes control diet exercise alone exclude Renal insufficiency calculate creatinine clearance le 50 ml/min Abnormal urinalysis result define : bacterial colony count great 100,000/ml 10 leukocyte per high power field 2 granular cast per low power field 10 red blood cell per high power field proteinuria &gt; + 1 ( equivalent &gt; 30 mg/dl ) ratio urine protein/urine creatinine &gt; 0.3 History chronic urinary tract infection recent urinary tract infection past six month History renal stone within past six month Acute hepatic disorder ( liver enzymes 50 % upper normal limit ) Chronic hepatitis within last two year ( positive hepatitis titer , Hepatitis A Virus , Hepatitis B Virus , Hepatitis C Virus , cytomegalovirus , EpsteinBarr virus abnormal immunological value ( positive immunoglobulin M ( IgM ) /IgG ) allow liver enzymes within normal range ) History liver disease within 2 year secondary drug intoxication cause include drug intoxication ( e.g . narcotic , cytostatics etc . ) Patients obvious symptom dehydration Abuse dependence drug hepatotoxic agent history drug screen . A history alcohol abuse within last 10 year also exclude patient Neoplasm currently active likely recur , need treatment ( except basal cell carcinoma ) Participation another clinical trial within last four week , previous participation talsaclidine trial ; patient enter panel 1 eligible inclusion panel 2 Pregnant lactate woman , woman childbearing potential use approved method contraception Poor ability patient caregiver/family comply protocol requirement assess investigator A list exclude medication attach protocol . These medication replace least four week trial medication start . If replacement clinically advisable , patient exclude trial In Germany , patient follow additional diagnosis exclude manifest angina pectoris well peripheral arterial circulatory disturbance</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>